Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
China · Delayed Price · Currency is CNY 43.19
-1.06 (-2.40%)
Apr 9, 2026, 3:04 PM CST
SHE:300584 Revenue
Nanjing Hicin Pharmaceutical had revenue of 162.95M CNY in the quarter ending September 30, 2025, with 31.45% growth. This brings the company's revenue in the last twelve months to 615.39M, up 22.98% year-over-year. In the year 2024, Nanjing Hicin Pharmaceutical had annual revenue of 504.36M, down -2.60%.
Revenue (ttm)
615.39M
Revenue Growth
+22.98%
P/S Ratio
8.42
Revenue / Employee
1.12M
Employees
548
Market Cap
5.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 504.36M | -13.47M | -2.60% |
| Dec 31, 2023 | 517.83M | -8.63M | -1.64% |
| Jan 1, 2023 | 526.47M | -51.85M | -8.97% |
| Jan 1, 2022 | 578.32M | -127.98M | -18.12% |
| Dec 31, 2020 | 706.30M | -218.24M | -23.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ZhuZhou QianJin Pharmaceutical Co.,Ltd | 3.63B |
| Jianmin Pharmaceutical Group | 3.37B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Bide Pharmatech | 1.32B |
| Zhuhai Rundu Pharmaceutical | 1.19B |
| Beijing Beilu Pharmaceutical | 1.13B |
| Teyi Pharmaceutical Group Co.,Ltd | 924.53M |
| ChengDu ShengNuo Biotec | 741.34M |